TaperCommunitymodafinil
Modafinil is a wakefulness-promoting agent (eugeroic) approved for narcolepsy, obstructive sleep apnea, and shift work sleep disorder. It is widely prescribed off-label for fatigue, ADHD, and cognitive enhancement.
100mg, 200mg
Tablets: 100mg, 200mg
Avoid in pregnancy — recent data suggest increased risk of congenital malformations
Mechanism is not fully understood. Modafinil weakly inhibits the dopamine transporter (DAT), increasing extracellular dopamine. It also affects orexin/hypocretin, histamine, norepinephrine, serotonin, and GABA systems involved in wakefulness regulation.
Modafinil has low classical dependence potential, but psychological reliance and rebound fatigue/sleepiness on discontinuation are common. A 2-4 week stepdown helps with rebound symptoms.
Modafinil is not classically habit-forming, but stopping abruptly often unmasks the underlying sleep disorder. Stepwise reductions over 2-4 weeks (e.g., 200 → 100 → 50mg) plus addressing the underlying condition (CPAP for OSA, sleep schedule for shift work) reduce rebound severity.
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Initial reduction | 1-2 weeks | Reduce from 200mg to 100mg daily. Most users tolerate this step well. |
| Middle reduction | 1-2 weeks | Reduce to 50mg (half-tablet) or alternate-day dosing. |
| Final discontinuation | 1-2 weeks | Discontinue. Consider lifestyle/sleep-hygiene support and address underlying conditions. |
1-2 days after dose reduction
3-7 days
Typically within 1-2 weeks for most symptoms
Rebound fatigue and low mood may persist 2-4 weeks; underlying sleep disorders re-emerge if unaddressed
Practical insights shared by members tapering Provigil. Not medical advice — always consult your prescriber.
Toxicity
Severe rash including Stevens-Johnson syndrome (rare). Cardiovascular effects (tachycardia, hypertension). Psychiatric effects including mania, psychosis, and suicidal ideation.
Provigil (modafinil) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Neutral, high-authority entity references.
Official prescribing information and safety notices.
Primary literature cited in this taper guide.
Evidence-based deprescribing and prescribing standards.
Clinician-facing references on tapering protocols.
Long-running communities documenting withdrawal experience.
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.
Pharmacokinetics
Rapidly absorbed, Tmax 2–4 hours. Food may delay absorption but does not affect overall bioavailability.
~0.9 L/kg
Hepatic metabolism, primarily via amide hydrolysis and CYP3A4 to inactive metabolites (modafinil acid, modafinil sulfone).
Renal (~80% as metabolites), <10% unchanged.
~60% (primarily albumin)
~50 mL/min
Browse our map of deprescribing-informed providers worldwide.